In a systematic review of seven studies in adults with type 2 diabetes, studies of tirzepatide or retatrutide pooled together emphasized a potential cardiovascular benefit across glycemia, body weight, lipids, blood pressure and renal parameters.
In plain wordsIn a review of seven studies in adults with type 2 diabetes, tirzepatide and retatrutide studies together pointed to a possible heart benefit.
- Peptide
- Tirzepatide
- Outcome
- Direction not reportedCardiovascular risk factors in included studies
- Study
n: not reported in source
- Outcome group
- Cardiometabolic risk factors · Cardiovascular
Source sentences
Results The seven included studies were assessed for bias with the Newcastle Ottawa scale, heterogenous, and emphasized the potential CV beneficial effect of type 2 DM (T2DM) therapies (glycemia, glycated A1c hemoglobin, body weight, lipid profile, blood pressure and renal parameter).
1 context sentence(design, population, supporting numbers)
Studies were selected if they (1) included patients with type 2 diabetes mellitus (DM) and CV risk; (2) patients that received either tirzepatide or retatrutide; and (3) provided sufficient information such as the corresponding 95% confidence intervals or at least a sufficient p-value.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.